Table 2.

Comparison of the risk of morality between APAP group and control group

Variable	APAP group				Control group				IRR (95% CI)	p-value
	n	Death	PY#	Rate*	n	Death	PY#	Rate*
All	3235	241	17,685.4	13.6	9705	94	55,497.5	1.7	8.1 (6.3–10.2)	<0.001
Age (years)
≤20	385	9	2276.7	4.0	1155	1	6905.8	0.1	27.3 (3.5–215.5)	0.002
21–39	2235	119	12,768.9	9.3	6705	23	39,663.3	0.6	16.1 (10.3–25.1)	<0.001
40–64	489	58	2259.2	25.7	1467	27	7358.4	3.7	7.0 (4.4–11.1)	<0.001
≥ 65	126	55	380.5	144.5	378	43	15,670.0	27.4	5.3 (3.5–7.9)	<0.001
Sex
Male	895	121	4601.9	26.3	2685	43	14,969.4	2.9	9.2 (6.5–13.0)	<0.001
Female	2340	120	13,083.6	9.2	7020	51	40,528.1	1.3	7.3 (5.3–10.1)	<0.001
Comorbidity†
DM	124	37	397.6	93.1	313	23	1331.5	17.3	5.4 (3.2–9.1)	<0.001
CAD	149	48	540.2	88.9	317	26	1346.4	19.3	4.6 (2.9–7.4)	<0.001
Stroke	84	27	323.6	83.4	137	22	501.6	43.9	1.9 (1.1–3.3)	0.025
HTN	248	71	912.0	77.9	666	47	2918.3	16.1	4.8 (3.3–7.0)	<0.001
Liver disease	396	54	1691.6	31.9	952	38	4633.6	8.2	3.9 (2.6–5.9)	<0.001
Renal disease	308	46	1338.5	34.4	633	18	3099.2	5.8	5.9 (3.4–10.2)	<0.001
Mental Disorder	1139	106	5379.8	19.7	1409	42	6831.1	6.2	3.2 (2.2–4.6)	<0.001
Cancer	75	28	249.1	112.4	145	13	683.1	19.0	5.9 (3.1–11.4)	<0.001
Follow up period
0–12 months	3235	104	3042.2	34.2	9705	20	9329.4	2.1	16.0 (9.9–25.7)	<0.001
1–2 year	2897	34	2761.6	12.3	8958	19	8576.6	2.2	5.6 (3.2–9.7)	<0.001
≥ 2 year	2641	103	11,881.6	8.7	8236	55	37,591.5	1.5	5.9 (4.3–8.2)	<0.001

#PY, person-years. *Rate, per 1000 person-years. †Participant may have multiple comorbidities. APAP, acetaminophen; IRR, incidence rate ratio; CI, confidence interval; DM, diabetes mellitus; CAD, coronary artery disease; HTN, hypertension